



COVID-19: Important updates and developments
Edited by Franco Rongioletti, MD and Leonard J. Hoenig, MD

Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination

Francesco Drago, MD^a, Francesco Broccolo, MD^b, Giulia Ciccarese, MD, PhD^{a,*}

^a *Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy*

^b *Department of Medicine and Surgery, School of Medicine, University of Milano-Bicocca, Monza, Italy*

Abstract Pityriasis rosea (PR), PR-like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. PR is a self-limiting exanthematous disease and herpes zoster is a treatable condition; therefore, their occurrence does not require discontinuation of the vaccination schedule. PR-LE is a hypersensitivity reaction and is, therefore, less predictable in its course. In the case of a booster dose, the clinical manifestation may not recur, may be different from PR-LE, or may present with systemic symptoms; however, in the case of PR-LE, the possibility of mild and predominantly cutaneous adverse events should not discourage all eligible candidates from receiving and completing the COVID-19 vaccination program, as such adverse reactions represent a small risk considering the possible severe and fatal outcome of COVID-19. We emphasize the relevance of looking for any viral reactivation in patients infected with SARS-CoV-2 who have skin eruptions. The search for viral reactivations could be useful not only for distinguishing between PR and PR-LE but also because viral reactivations may contribute to a patient's systemic inflammation and influence the course of the disease.

© 2022 Elsevier Inc. All rights reserved.

Introduction

Numerous skin manifestations have been reported during the coronavirus disease 2019 (COVID-19) pandemic, which was caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).^{1,2} Pityriasis rosea (PR) and PR-like eruptions (PR-LE) have been repeatedly described,¹ and authors have recorded a fivefold increase in the number of PR cases during the pandemic.² PR and PR-LE have also been frequently described following different COVID-19 vaccines.³⁻⁶ In addition, an increase in herpes zoster (HZ)

cases and other viral reactivations in patients with COVID-19 and an increase in HZ cases following COVID-19 vaccinations have been reported.¹ These observations raise many critical issues, namely the following: Is it possible to distinguish between PR and PR-LE? Can SARS-CoV-2 infection trigger viral reactivations? Why do PR, PR-LE, and HZ occur following COVID-19 vaccination?

PR, PR-LE, and HZ during COVID-19: the issue of viral reactivations

PR is a common, self-limiting exanthematous disease associated with the endogenous systemic reactivation of human herpesvirus 6 (HHV-6) and/or HHV-7. The disease typically begins with a single, erythematous plaque followed

* Corresponding author.

E-mail address: giuliaciccarese@libero.it (G. Ciccarese).

by a secondary eruption with lesions on the cleavage lines of the trunk (configuration as a “theatre curtain”). In the classic form of PR, duration may vary from 2 weeks to a few months.⁷ Although some authors have not been able to demonstrate this association, the relationship of PR with systemic active HHV-6 and HHV-7 infection is based on many and consistent observations. Several studies have identified HHV-6 and HHV-7 DNA by polymerase chain reaction (PCR) and real-time calibrated quantitative-PCR in plasma, peripheral blood mononuclear cells and skin samples of patients with PR⁸; mRNA expression and specific antigens have been documented in PR skin lesions by *in situ* hybridization and immunohistochemistry respectively.^{8,9} In addition, a plasma load of HHV-6 and HHV-7, a direct marker of viral replication, is associated with the development of systemic symptoms as well as with a significant reduction of the humoral neutralizing antibodies, further supporting that PR is associated with the endogenous reactivation of HHV-7 or HHV-6 infection.⁸ Herpesvirus virions in various stages of morphogenesis were detected by electron microscopy in PR skin lesions¹⁰ and in the supernatant of co-cultured peripheral blood mononuclear cells of patients with PR.⁸ Lastly, the increased levels of interferon (IFN) α , interleukin 17 (IL17), IFN- γ , vascular endothelial growth factor (VEGF), and C-X-C motif chemokine ligand 10 (CXCL10) in the sera of patients with PR could again support a viral role in PR pathogenesis.¹¹ The fact that other authors have reported contradictory results in their studies on PR is likely to be attributed to the sensitivity and specificity of the methods used. Sampling the patient in the acute phase or in convalescence, for example, is not immaterial, and the type of biologic material studied (peripheral blood mononuclear cells, plasma, tissue) and its combination with the method of study are of paramount importance.

Conversely, PR-LE is not a true form of PR. Although it is often difficult to distinguish clinically the two eruptions, PR-LE has a completely different pathogenesis. Unlike PR, PR-LE is not associated with HHV-6 and/or HHV-7 systemic reactivation, but it has a pathogenesis more similar to that of other drug eruptions.^{12,13} PR-LE can be compared to PR just as morbilliform drug eruptions to measles. Clinical, histopathologic, and, primarily, virologic criteria have been proposed for distinguishing between the two forms (Table 1).^{12,13} Remarkably, in patients with skin eruptions during SARS-CoV-2 infection or after vaccination, virologic investigations are crucial not only to distinguish between PR and PR-LE but also to know whether SARS-CoV-2 or COVID-19 vaccination may have reactivated HHV-6 and/or HHV-7. Regrettably, the authors describing cases of PR and PR-LE during COVID-19 and following COVID-19 vaccinations did not perform specific investigations to search for HHV-6/HHV-7 reactivation.^{3-6,14} HHV-6, HHV-7, and Epstein-Barr virus concurrent systemic reactivations have been detected in a patient with PR and COVID-19¹⁵; likewise, Epstein-Barr virus systemic reactivation has been doc-

umented in a patient with diffuse papulosquamous eruption and COVID-19.¹⁶

The varicella zoster virus (VZV) reactivation explains the high number of cases of HZ observed during SARS-CoV-2 infection.¹ The psychological stress linked to the pandemic and the immunosuppression associated with SARS-CoV-2 infection may act enabling the reactivation of latent viral infections.¹⁷ Actually, SARS-CoV-2 infection decreases number and efficiency of T lymphocytes, particularly CD4⁺ T cells, CD8⁺ T cells and natural killer cells. Conversely, Th17 cells, interleukin 17A (IL17A) and the Th17/T regulatory (Treg) cell ratio increases in peripheral blood of patients with COVID-19.¹⁸⁻²⁰ Similarly, higher levels of circulating Th17 cells and of IL17A have been detected in the serum of patients with HZ compared to normal participants.²¹ A recent study, using bioinformatic analyses of COVID-19 and HZ-associated genes, shed new light on the pathogenetic mechanisms by which SARS-CoV-2 can promote VZV reactivation.²² By analyzing the list of genes involved in the pathogenesis of COVID-19 and HZ, a series of disease-related genes were found that overlapped. A possible genetic crosstalk during VZV and SARS-CoV-2 infections has been discovered with additive and synergistic interactions leading to an excessive Th17 differentiation and consequent increase of the circulating IL17A.²² This abnormal interleukin-17 genetic signaling is stronger in case of simultaneous occurrence of COVID-19 and HZ compared to one of the two diseases taken individually.²² As a result, the augmented Th17 cells differentiation, IL17A signaling and Th17/Treg cell ratio could explain the increased risk of HZ in patients with COVID-19. It has been demonstrated that an imbalance between Th17/Treg cells and increased level of IL17 could directly support latency, reactivation and lytic infection of VZV and other herpesviruses.²³

IL17 is the main cytokine produced by Th17 cells, a T-cell subset involved in controlling opportunistic extracellular bacterial infections and fungi and pathogenic invasion at different mucosal sites.²⁴ Th17 role in immune response against viruses is multifaceted, not yet fully understood and, in some ways, contradictory. Stimulated by cytokines from dendritic cells, Th17 cells and IL17 increase during acute or chronic viral infections but their role is generally considered harmful to the host.²⁵ IL17 can promote viral persistence increasing both pro-inflammatory and anti-apoptotic cytokines and impairing target cell destruction by cytotoxic CD8⁺T cells.²⁵ Decreasing the production of IL2 and interferon- γ , IL17 can inhibit Th1 differentiation, prevent viral clearance and cause inflammatory tissue damage. Th17 cells and IL17 can increase not only during HZ or herpes simplex virus (HSV) infections but also during other infections, favoring viral replication and persistence.²⁶⁻²⁸ Conversely, in viral infections such as rotavirus or influenza, Th17 cells may play a defensive role contributing to viral clearance.²⁹⁻³¹ Generally, the role of Th17 cells in viral infections changes depending on the host's genetic background, on the virus type and on the

Table 1 Clinical, histopathologic, and virologic criteria for distinguishing between PR and PR-LE		
	Classic PR	PR-LE
Pathogenesis	HHV-6/HHV-7 systemic reactivation	Adverse reaction to a drug/vaccine
Lesions morphology	Erythematous papulosquamous lesions	Dusky-red macules/papules with occasional desquamation
Marginal collarettes of scales	Present in most lesions	Less common
Herald patch	Present in most cases	Present in 25% of cases
Distribution of the lesion	“Theater curtain” or “Christmas tree” pattern on the trunk	Lesions diffuse and more confluent on trunk, limbs, and face
Appearance of new lesions	Development in crops over a period of 1-2 wk after the onset of the herald patch	Eruption reaches the peak in a few days
Oropharyngeal lesions	Possible (16% of cases)	Frequent (>50% of cases)
Itch	Mild or absent	Present and sometimes intense
Prodromal symptoms	Frequently present	Absent
Routine laboratory findings	Within normal ranges	Occasional peripheral eosinophilia (42% of cases)
Virologic investigations	HHV-6/HHV-7 DNA present in plasma; immunoglobulin M antibodies against HHV-6/HHV-7 occasionally positive in serum	No signs of HHV-6/HHV-7 systemic reactivation in the plasma or serum
Histopathologic features	Epidermal focal parakeratosis and spongiosis; few scattered dyskeratotic keratinocytes; extravasated red blood cells and perivascular infiltrate of lymphocytes, histiocytes, and occasionally eosinophils in the papillary dermis	Occasional features of interface dermatitis with scattered single necrotic keratinocytes; more dyskeratotic keratinocytes (occasionally in clusters); acrosyringeal presence of necrotic keratinocytes; more abundant and diffuse perivascular infiltrate of lymphocytes, histiocytes, and eosinophils in the papillary and reticular dermis; enlargement of endothelial cells
Duration	45 d on average	14 d on average after discontinuation of the drug
Therapy	Rest	Drug withdrawal

HHV, human herpesvirus; PR, pityriasis rosea; PR-LE, pityriasis rosea–like eruptions.

Th17/Treg cell ratio. The Th17/Treg cell ratio was statistically significantly higher in patients during HZ than controls and this imbalance may play a role in the pathogenesis of HZ.²¹

Conflicting findings on the Th17/Treg cell ratio have been reported, possibly depending on the disease activity, because the amount of Treg cells varies according to the acute or chronic stage of the viral infection.³²⁻³⁴ The burst of HZ with VZV active replication may act inducing and activating Tregs which, in turn, can control the Th17 initial immune response. Tregs induction is a common event during viral infections, accounting for the transient immunosuppression that can occur during the illness and after recovery.³⁵ A similar mechanism orchestrated by dysregulated Th17 immune response could also mediate HHV-6 and/or HHV-7 reactivation and the occurrence of PR during COVID-19. As well as in HZ, Th17 cells and IL17 are increased in the acute stage of PR and their amount is related to severity and duration of the disease.^{36,37} In addition to creating a dysregulated Th17 immune response, SARS-CoV-2 infection may have a direct

trans-activating role, triggering HHV-6 and/or HHV-7 reactivation and causing, indirectly, the onset of PR.³⁸ Really, it has been described in critically ill patients with COVID-19 that the concurrent reactivation of other HHV, such as HSV-1 and VZV, can influence disease outcomes resulting in sudden worsening of the symptoms.³⁹⁻⁴¹

PR, PR-LE, and HZ following COVID-19 vaccination

PR, PR-LE, and HZ have also been described following COVID-19 vaccination.^{3-6,14} PR and PR-LE have been reported following influenza, diphtheria, tuberculosis, poliomyelitis, tetanus, yellow fever, hepatitis A, rabies, Japanese encephalitis, and human papilloma virus vaccines. Usually, PR develops a few weeks after vaccination whereas PR-LE after a few days. This different latency is due to the time required for HHV-6 or HHV-7 reactivation resulting in PR longer than the immunological hypersensitivity reaction originating PR-LE.^{42,43} Unfortunately, also in PR and PR-LE cases occurring following COVID-19 vaccination the mark-

ers of HHV-6 and HHV-7 systemic reactivation, such as detection of HHV 6/7 DNA in plasma and detection of positive IgM antibodies against HHV-6/7 in serum, have never been investigated.⁴⁴ VZV and HSV reactivations accounted for 3% to 14% of cutaneous reactions after mRNA COVID-19 and Oxford/AstraZeneca AZD1222 vaccines in a large case series of participants.^{45,46} VZV reactivation was more frequent after BNT162b2 (Pfizer) vaccination and in men. The time elapsed before a viral reactivation was on average 7 days and reactivation was more frequent after the first dose than after the second (63% versus 37% of cases).^{45,46} paragraphThe pathogenesis of HZ, PR, and PR-LE after vaccination is unknown. Generally, adverse events following immunization may be fortuitous or closely related to the vaccine. In genetically susceptible individuals, humoral and cellular adaptive immune response and the amount of plasma cytokines induced by vaccines may cause immune dysregulation which may play a role in the reactivation of latent VZV, HHV-6, and HHV-7 infection. This phenomenon may be compared to the so-called “immune reconstitution inflammatory syndrome” (IRIS), following the introduction of antiretroviral therapy in patients infected with HIV, and associated with paradoxical worsening or reactivation of pre-existing infections.⁴⁷⁻⁴⁹ paragraphThe pathogenesis of IRIS is still unknown but amplifying inflammatory reaction with increased plasma levels of several cytokines (primarily interleukin-6 and soluble CD30) and reduction of T-reg cells signaling play a role. HSV-2 reactivation and increased frequency of HSV-2 shedding as well as VZV, HHV-8, and cytomegalovirus reactivation have been related to IRIS.⁴⁷⁻⁴⁹ Strongly stimulating immune response and polarizing it to a committed-induced T cell response against a definite infectious agent, a vaccine may temporarily distract the T-cell-mediated control on the latent infections, such as VZV, HHV-6, and HHV-7, which may reactivate causing PR.^{42,43} paragraphA dysregulated Treg cells function, depending on the host’s immunologic background, may contribute to an exaggerated cytokine response to COVID-19 vaccination encouraging viral reactivation. Indeed, Treg cells coordinate not only immune response against viral infections but also dampen and coordinate foreign antigen specific immunity following vaccination.³⁴ On the contrary, PR-LE may occur as a delayed hypersensitivity response to a vaccine as well as a drug. paragraphA possible mechanism is molecular mimicry between a viral epitope such as SARS-CoV-2 spike glycoprotein, viral vector or a vaccine ingredient and host proteins that could result in a T-cell-mediated hypersensitivity skin reaction.⁵⁰ One group a⁵¹ detected by Immunohistochemistry SARS-CoV-2 spike protein in endothelial cells and perivascular lymphocytes in the skin of a patient with PR-LE and COVID-19. They defined PR-LE the skin manifestation and did not perform specific investigations for HHV-6 and HHV-7. These findings suggest that SARS-CoV-2 viral infection or immune response against spike protein-based vaccines may cause PR-LE.⁵¹

Conclusions

PR, PR-LE, and HZ have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. Because PR is a self-limiting exanthem and HZ is a treatable condition, their occurrence does not require discontinuation of the vaccination schedule. Regarding PR, in our experience, it is unlikely that HHV-6 and HHV-7 reactivation occurs following the booster dose.^{43,44} Conversely, PR-LE is a hypersensitivity reaction and, as such, is less predictable. In the case of booster dose, the clinical manifestation may not recur, be different from PR-LE, or present with systemic symptoms. Overall, the possibility of mild and self-limiting cutaneous adverse events should not discourage all eligible candidates from receiving COVID-19 vaccination; such adverse reactions represent a small risk in relation to the possible severe and fatal outcome of COVID-19.

Lastly, we emphasize the relevance of looking for any viral reactivations in patients infected with SARS-CoV-2 who have cutaneous manifestations such as viral exanthems; the search for viral reactivations could be useful not only for distinguishing between PR and PR-LE but also because they may contribute to a patient’s systemic inflammation and influence the course of the disease itself.³⁹⁻⁴¹

Conflict of interest

The authors have no conflicts of interest to disclose.

References

- Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol.* 2020;183:71–77.
- Dursun R, Temiz SA. The clinics of HHV-6 infection in COVID-19 pandemic: pityriasis rosea and Kawasaki disease. *Dermatol Ther.* 2020;33:e13730.
- Akdaş E, İltner N, Ögüt B, Erdem Ö. Pityriasis rosea following CoronaVac COVID-19 vaccination: a case report. *J Eur Acad Dermatol Venereol.* 2021;35:e491–e493.
- Cyrenne BM, Al-Mohammed F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 Vaccine. *J Eur Acad Dermatol Venereol.* 2021;35:e546–e548.
- Abdullah L, Hasbani D, Kurban M, Abbas O. Pityriasis rosea after mRNA COVID-19 vaccination. *Int J Dermatol.* 2021;60:1150–1151.
- Carballido Vázquez AM, Morgado B. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination. *Br J Dermatol.* 2021;185:e34.
- Drago F, Ciccarese G, Rebora A, Broccolo F, Parodi A. Pityriasis rosea: a comprehensive classification. *Dermatology.* 2016;232:431–437.
- Broccolo F, Drago F, Careddu AM, et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. *J Invest Dermatol.* 2005;124:1234–1240.
- Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6. *J Invest Dermatol.* 2002;119:793–797.

10. Drago F, Malaguti F, Ranieri E, Losi E, Rebora A. Human herpes virus-like particles in pityriasis rosea lesions: an electron microscopy study. *J Cutan Pathol*. 2002;29:359–361.
11. Drago F, Ciccarese G, Broccolo F, Ghio M, Contini P, Thanasi H. The role of cytokines, chemokines, and growth factors in the pathogenesis of pityriasis rosea. *Mediators Inflamm*. 2015;2015:438963.
12. Drago F, Ciccarese G, Parodi A. Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them? *JAAD Case Rep*. 2018;4:800–801.
13. Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea and pityriasis rosea-like eruption: can they be distinguished? *J Dermatol*. 2014;41:864–865.
14. Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series. *Dermatol Ther*. 2021 Nov 23:e15225.
15. Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. *J Med Virol*. 2021;93:1850–1851.
16. Sanchez A, Sohler P, Benghanem S, et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection. *JAMA Dermatol*. 2020;156:819–820.
17. Shanshal M, Ahmed HS. COVID-19 and herpes simplex virus infection: a cross-sectional study. *Cureus*. 2021;13:e18022.
18. De Biasi S, Meschiari M, Gibellini L, et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. *Nat Commun*. 2020;11:3434.
19. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*. 2020;71:762–768.
20. Martonik D, Parfieniuk-Kowarda A, Rogalska M, Flisiak R. The role of Th17 response in COVID-19. *Cells*. 2021;10:1550.
21. Kim MS, Kim DJ, Na CH, Shin BS. A study of the changes of t helper 17 cells and regulatory t cells in herpes zoster. *Ann Dermatol*. 2017;29:578–585.
22. Yu X, Li L, Chan MTV, Wu WKK. Bio-informatic analyses suggest augmented interleukin-17 signaling as the mechanism of COVID-19-associated herpes zoster. *Environ Sci Pollut Res Int*. 2021;28:65769–65775.
23. Mei XX, Lei SS, Xu L, Wu S, Gu HP, Du Y. Herpes simplex virus type I-infected disorders alter the balance between Treg and Th17 cells in recurrent herpes labialis patients. *Int J Immunopathol Pharmacol*. 2020;34:1–9.
24. Kolls JK, Khader SA. The role of Th17 cytokines in primary mucosal immunity. *Cytokine Growth Factor Rev*. 2010;21:443–448.
25. Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. *J Exp Med*. 2009;206:313–328.
26. Christensen-Quick A, Lafferty M, Sun L, Marchionni L, DeVico A, Garzino-Demo A. Human Th17 cells lack HIV-inhibitory RNAses and are highly permissive to productive HIV infection. *J Virol*. 2016;90:7833–7847.
27. Xue-Song L, Cheng-Zhong L, Ying Z, Mo-Bin W. Changes of Treg and Th17 cells balance in the development of acute and chronic hepatitis B virus infection. *BMC Gastroenterol*. 2012;12:43.
28. Maina EK, Bukusi EA, Martha S, et al. The relative balance between Th17 and regulatory T cell subsets is critical for progression of HIV infection. *J AIDS Clin Res*. 2014;5:1–7.
29. Smiley KL, McNeal MM, Basu M, Choi AH, Clements JD, Ward RL. Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). *J Virol*. 2007;81:3740–3748.
30. Hamada H, Garcia-Hernandez Mde L, Reome JB, et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. *J Immunol*. 2009;182:3469–3481.
31. Paiva IA, Badolato-Corrêa J, Familiar-Macedo D, de-Oliveira-Pinto LM. Th17 cells in viral infections—friend or foe? *Cells*. 2021;10:1159.
32. Xing Q, Hu D, Shi F, Chen F. Role of regulatory T cells in patients with acute herpes zoster and relationship to postherpetic neuralgia. *Arch Dermatol Res*. 2013;305:715–722.
33. Toka FN, Suvas S, Rouse BT. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. *J Virol*. 2004;78:13082–13089.
34. Kursar M, Bonhagen K, Fensterle J, et al. Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. *J Exp Med*. 2002;196:1585–1592.
35. Schneider-Schaulies S, Niewiesk S, Schneider-Schaulies J, ter Meulen V. Measles virus induced immunosuppression: targets and effector mechanisms. *Curr Mol Med*. 2001;1:163–181.
36. Gangemi S, Cannav SP, Guarneri F. The CX3Cchemokine fractalkine (CX3CL1) is detectable in serum of patients affected by active pityriasis rosea. *J Eur Acad Dermatol Venereol*. 2006;12:1366–1367.
37. Mokadem SA, Ghonemy S, Zidan A, Abd El Aleem G. The role of interleukin-22 in pityriasis rosea. *Clin Exp Dermatol*. 2017;42:30–35.
38. Ciccarese G, Parodi A, Drago F. SARS-CoV-2 as possible inducer of viral reactivations. *Dermatol Ther*. 2020;33:e13878.
39. Xu R, Zhou Y, Cai L, et al. Co-reactivation of human herpesvirus alpha subfamily (hsv i and vzv) in critically ill patient with COVID-19. *Br J Dermatol*. 2020;183:1145–1147.
40. Meyer A, Buetti N, Houhou-Fidouh N, et al. HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. *Crit Care*. 2021;25:417.
41. Franceschini E, Cozzi-Lepri A, Santoro A, et al. Herpes simplex virus re-activation in patients with SARS-CoV-2 pneumonia: a prospective, observational study. *Microorganisms*. 2021;9:1896.
42. Drago F, Ciccarese G, Javor S, Parodi A. Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature. *J Eur Acad Dermatol Venereol*. 2016;30:544–545.
43. Drago F, Ciccarese G, Rebora A, Parodi A. Pityriasis rosea following human papillomavirus vaccination. *Braz J Infect Dis*. 2015;19:224–225.
44. Drago F, Broccolo F, Ciccarese G. Comment on a case of pityriasis rosea shortly after Moderna COVID-19 vaccination. *Int J Infect Dis*. 2022 Jan 3 S1201-9712(21)01260-1.
45. Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. *Br J Dermatol*. 2022;186:142–152.
46. McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. *J Am Acad Dermatol*. 2021;86:113–121.
47. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. *AIDS Res Ther*. 2007;4:9.
48. Drago F, Javor S, Bruzzone L, Drago F, Parodi A, Picciotto A. Pityriasis rosea in a hepatitis B-positive patient treated with pegylated interferon α 2a: report of a case and review of the literature. *Dermatology*. 2014;228:10–13.
49. Tobian AA, Grabowski MK, Serwadda D, et al. Reactivation of herpes simplex virus type 2 after initiation of antiretroviral therapy. *J Infect Dis*. 2013;208:839–846.
50. Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M. Antigen presentation of mrna-based and virus-vectored SARS-CoV-2 vaccines. *Vaccines (Basel)*. 2021;9:848.
51. Welsh E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, Arvizu-Rivera RI. SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19. *Br J Dermatol*. 2021;184:1194–1195.